ENTITY
Myovant Sciences

Myovant Sciences (MYOV US)

5
Analysis
Health CareJapan
Myovant Sciences Ltd. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant Sciences develops relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis-associated pain.
more
25 Oct 2022 12:48

Sumitomo/​Myovant: Agreed Minorities Takeout at $27

There is a willing buyer, Sumitomo, which has increased its offer by 18.7% vs. the initial approach. The market believes the offer will succeed and...

Share
bullishSumitomo Pharma
18 Oct 2022 17:49

Sumitomo Dainippon Pharma Co (4506 JP): Myovant Is Crucial for Post-Latuda Growth Momentum

As Sumitomo is not expected to launch any new in-house product until FY24, the company needs Myovant’s already marketed products to maintain its...

Logo
272 Views
Share
08 Oct 2022 06:22

Sumitomo/Myovant: Minorities Takeout

The question is whether Orgovyx could become a blockbuster. The market certainly thinks so, there may be both further upside potential in the...

Share
07 Oct 2022 18:30

Myovant Sciences (MYOV US): Rejects Sumitomo’s $2.5B Bid; Remains Open for Better Offer

Myovant has turned down acquisition offer from its largest shareholder, leading to share price volatility. A revised offer or a fresh offer from...

Logo
404 Views
Share
bullishS&P 500 INDEX
05 Oct 2022 04:20

Another Bear Market Rally Brewing?; Stick With Biotech and Construction/Engineering Names

Early indications suggest another bear market rally in $SPX, and potentially that the lows are in, helped by short-term bearish engulfing patterns...

Logo
300 Views
Share
No more insights
x